openPR Logo
Press release

ATTR Amyloidosis Pipeline 2025: Innovative Clinical Developments by 3+ Global Leaders - DelveInsight | Featuring Intellia Therapeutics, YolTech Therapeutics, Alexion Pharmaceuticals

10-17-2025 06:06 PM CET | Associations & Organizations

Press release from: ABNewswire

ATTR Amyloidosis Pipeline 2025

ATTR Amyloidosis Pipeline 2025

DelveInsight's, "ATTR Amyloidosis - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ATTR Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As ATTR Amyloidosis becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more effective therapies continues to grow. DelveInsight reports that more than three pharmaceutical and biotech companies are actively advancing over three therapeutic candidates targeting ATTR Amyloidosis. These candidates are in various stages of clinical and preclinical development, reflecting significant innovation and dedication to addressing this major public health concern.

The "ATTR Amyloidosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive strategic overview of the current R&D landscape, examining clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. It is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving ATTR Amyloidosis therapeutics market and the breakthroughs shaping its future.

Explore the Cutting-Edge Landscape of ATTR Amyloidosis Drug Development @ https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the ATTR Amyloidosis Pipeline Report

*
DelveInsight's report on the ATTR Amyloidosis pipeline highlights a dynamic landscape, with over three active companies developing multiple therapeutic candidates for ATTR Amyloidosis.

*
In March 2025, Alnylam announced FDA approval of AMVUTTRA Registered (vutrisiran), the first RNAi therapy shown to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in adults with ATTR Amyloidosis with cardiomyopathy (ATTR-CM).

*
Leading companies, including Intellia Therapeutics, YolTech Therapeutics, Alexion Pharmaceuticals, and others, are actively pursuing novel therapies to advance the ATTR Amyloidosis treatment landscape. Notable pipeline candidates in various stages of development include NTLA-2001, YOLT-201, and additional therapies.

ATTR Amyloidosis Overview:

ATTR-CM is a form of systemic amyloidosis characterized by the accumulation of misfolded transthyretin (TTR) protein in the heart, leading to impaired cardiac function. While light-chain (AL) amyloidosis can also affect the heart, transthyretin amyloidosis is the more common cause of cardiac involvement.

The disease can impact multiple organs, though in some cases the heart is the only affected site. Historically, diagnosing ATTR-CM has been difficult due to limited diagnostic tools. However, advances in bone scintigraphy and the development of new therapies have improved diagnostic accuracy. Consequently, ATTR-CM is now more frequently detected, particularly in patients with heart failure with preserved ejection fraction (HFpEF), a population previously not recognized as high-risk.

Download the ATTR Amyloidosis sample report to know in detail about the ATTR Amyloidosis treatment market @ https://www.delveinsight.com/sample-request/attr-amyloidosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

ATTR Amyloidosis Pipeline Analysis

The ATTR Amyloidosis pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the ATTR Amyloidosis Market.

*
Categorizes ATTR Amyloidosis therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging ATTR Amyloidosis drugs under development based on:

*
Stage of development

*
ATTR Amyloidosis Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
ATTR Amyloidosis Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
ATTR Amyloidosis Licensing agreements

*
Funding and investment activities supporting future ATTR Amyloidosis market advancement.

Unlock key insights into emerging ATTR Amyloidosis therapies and market strategies here: https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

ATTR Amyloidosis Emerging Drugs

*
NTLA-2001: Intellia Therapeutics

NTLA-2001 is an innovative CRISPR/Cas9-based therapy under development as a potential single-dose treatment for transthyretin (ATTR) amyloidosis. Its mechanism targets the TTR gene, silencing it to prevent the production of the misfolding-prone transthyretin protein that drives the disease. Importantly, NTLA-2001 represents the first experimental CRISPR therapy designed for systemic in vivo gene editing, allowing direct modification of genes within human cells throughout the body.

*
YOLT-201: YolTech Therapeutics Co., Ltd

YOLT-201 Injection is an experimental therapy for transthyretin (ATTR) amyloidosis that uses lipid nanoparticles (LNPs) to deliver genetic material into the body. The formulation includes ionizable lipids and other components that encapsulate mRNA and single-guide RNA (sgRNA) to form LNPs.

After intravenous administration, Apolipoprotein E (ApoE) binds to the LNP surface in the bloodstream, allowing liver cells-which express the LDLR receptor-to take up the nanoparticles via endocytosis, creating intracellular compartments known as endosomes.

ATTR Amyloidosis Pipeline Therapeutic Assessment

ATTR Amyloidosis Assessment by Product Type

- Mono

- Combination

- Mono/Combination

ATTR Amyloidosis By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

ATTR Amyloidosis Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

ATTR Amyloidosis Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging ATTR Amyloidosis therapies and key ATTR Amyloidosis companies [https://www.delveinsight.com/sample-request/attr-amyloidosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. ATTR Amyloidosis Current Treatment Patterns

4. ATTR Amyloidosis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. ATTR Amyloidosis Late-Stage Products (Phase-III)

7. ATTR Amyloidosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. ATTR Amyloidosis Discontinued Products

13. ATTR Amyloidosis Product Profiles

14. ATTR Amyloidosis Key Companies

15. ATTR Amyloidosis Key Products

16. Dormant and Discontinued Products

17. ATTR Amyloidosis Unmet Needs

18. ATTR Amyloidosis Future Perspectives

19. ATTR Amyloidosis Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the ATTR Amyloidosis pipeline reports offerings [https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=attr-amyloidosis-pipeline-2025-innovative-clinical-developments-by-3-global-leaders-delveinsight-featuring-intellia-therapeutics-yoltech-therapeutics-alexion-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ATTR Amyloidosis Pipeline 2025: Innovative Clinical Developments by 3+ Global Leaders - DelveInsight | Featuring Intellia Therapeutics, YolTech Therapeutics, Alexion Pharmaceuticals here

News-ID: 4229673 • Views:

More Releases from ABNewswire

East Texas's Premier Wrongful Death Legal Advocate McKayLawTx.com
East Texas's Premier Wrongful Death Legal Advocate McKayLawTx.com
McKay Law Firm (McKayLawTX.com) has solidified its position as East Texas's leading wrongful death law firm, delivering justice for grieving families through a combination of aggressive litigation, substantial verdicts and settlements, and an unwavering commitment to client care. TYLER, TEXAS - October 17, 2025 - With a track record of securing numerous multi-million dollar verdicts and settlements in wrongful death cases throughout the East Texas region, McKay Law Firm has become
A Life Carved from Silence - Fr David Jones Releases
A Life Carved from Silence - Fr David Jones Releases "Ad Maiestatem," a Poetic T …
Spanning 44 years from the Trappist monastery to a Irish hermitage, this collected poetry transforms silence, faith, and human longing into a resonant offering of beauty and grace. Ad Maiestatem (Collected Poetry of Fr David Jones) gathers more than four decades of spiritual and poetic reflection from a man who lived between cloistered silence and the restless search for divine beauty. Written from 1980 to 2024, these poems follow Fr Jones's
Cytomegalovirus (CMV) Infection Pipeline 2025: Innovative Clinical Developments by 15+ Global Leaders - DelveInsight | Featuring ModernaTX, Helocyte, VBI Vaccines, SpyBiotech, Vir Biotechnology, Glaxo
Cytomegalovirus (CMV) Infection Pipeline 2025: Innovative Clinical Developments …
DelveInsight's, "Cytomegalovirus (CMV) Infection Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus (CMV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. As Cytomegalovirus (CMV) infection continues to rise globally and
Hepatic-Colorectal Metastasis Pipeline 2025: Pioneering Clinical Developments by Leading Global Players - DelveInsight | Highlighting Sotevtamab, Nelitolimod, PDC*Neo
Hepatic-Colorectal Metastasis Pipeline 2025: Pioneering Clinical Developments by …
DelveInsight's, "Hepatic - Colorectal Metastasis - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatic - Colorectal Metastasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. With the prevalence of hepatic-colorectal metastasis

All 5 Releases


More Releases for TTR

SWATCH TTR TOUR CHAMPION CROWNED IN DAYS
Vermont, USA - March 16th, 2009: The time has come to crown the men’s Swatch TTR Tour Champion at the prestigious 6Star Burton US Open. After a highly charged season, Shaun White (USA) and Peetu Piiroinen (FIN) have emerged as the two Title contenders, but only one will walk away victorious after Sunday’s Slopestyle Final. However, the Halfpipe finals on Saturday will already play an important and
Kevin Pearce new Swatch TTR World Tour Champion
Stratton, VT, USA - March 21st, 2008: After a full-out season of close calls and flawless victories, US snowboarder Kevin Pearce charged through the opposition, defeating his challengers and rising to the occasion to become the new 07/08 Men’s Swatch TTR World Snowboard Tour Champion. Kevin Pearce, a Vermont native, was crowned at 04.30 pm U.S. EST at the base of Stratton Mountain in front of a mass of spectators
TTR FOUR(4)STAR BUDWEISER BUDRIDERS’ RIVERJUMP
Livigno, Italy. TTR FOUR(4)STAR event, the 2nd Edition Budweiser Budriders’ Riverjump, set the scene for Yale Cousino (USA) to display his Slopestyle skills blowing the field away to win the contest title and 700 TTR Ranking Points at Livigno, Italy, 8th -10th March, 2007. Set in one of Europe’s best Slopestyle parks, built with top Italian craftsmanship, the Mottolino Livigno snowpark consisted of one car to slide/to bonk, two rails
TTR FOUR(4)STAR BILLABONG WORLD JUNIOR PRO
Leysin, Switzerland. Unexpected stormy winds finally forced organizers of TTR FOUR(4)STAR 4th annual Billabong World Junior Pro to cancel the Slopestyle Finals at the Mont de Chaux Snowpark, Leysin, 6th-11th March, 2007, and take the semi-final results to announce the Franck April (CAN) and Marie Hucal (USA) the Billabong World Junior Champions. Bad weather affected Saturday’s original schedule so Billabong World Junior Pro organizers and riders postponed the Finals to a
INTRODUCING HOT NEW TTR FEATURES: MYSPACE, MEDIA FRIENDS, BRAND PARTNER & TTR TO …
Innsbruck, Austria. On the quest to progress, Ticket To Ride (TTR) World Snowboard Tour launches brand spanking new features on the official website www.ttrworldtour.com, including TTR Brand Partner Ranking & Media ‘Friends’ sections and TTR’s very own myspace community. Sure to shake the industry is a team manager’s dream – the Men & Women TTR Brand Partner Top 5. Composed of official Platinum and Gold TTR Brand Partners, the ranking is
TTR FIVE(5)STAR OAKLEY ARCTIC CHALLENGE
SENSATIONAL NEWS FROM TTR FIVE(5)STAR OAKLEY ARCTIC CHALLENGE AS TERJE HAAKONSEN BREAKS WORLD RECORD FOR HIGHEST AIR & KEVIN PEARCE WINS TITLE TO BECOME THE NEW TTR TOUR LEADER Oslo, Norway. The TTR FIVE(5)STAR Oakley Arctic Challenge 2007 goes down as one of the most important chapters in snowboarding history as Terje Haakonsen (NOR) sets a new World Record for the Highest Air at an incredible 9.8-metres – whilst Kevin Pearce